Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00777543
Other study ID # 08-3-079
Secondary ID NL26116.068.08
Status Completed
Phase N/A
First received
Last updated
Start date November 2008
Est. completion date December 2009

Study information

Verified date November 2009
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to investigate the effect of pretreatment of bran on improving the bioavailability of ferulic acid in wholegrain breads containing bran. As secondary endpoints we will investigate the changes in plasmatic antioxidant capacity, anti-inflammatory effects, colonic metabolites from ferulic acid and short chain fatty acids (SCFA).


Description:

Rationale: Whole grain consumption has been associated with a lower risk of developing metabolic syndrome, cardiovascular disease, type 2 diabetes and some type of cancers. Whole grain is a good source of antioxidant compounds such as ferulic acid, which has been considered its major antioxidant. Ferulic acid is also the major phenolic compound in wheat grain, it is mainly located in the bran, more precisely in the cell walls of the aleurone layer and overall bran layers. Most of the ferulic acid is covalently bound to the indigestible cell wall polysaccharides, which limits the bioavailability of ferulic acid from cereal products to the merely form of free ferulic acid.

Processing possibilities in the development of cereal products might be used to optimize the bioavailability of ferulic acid in humans and the possible health effect of the wholegrain product.

An innovative processing in bread making has been developed. The processing consisted of pretreatments of the bran with an enzymatic mixture and yeast fermentation before its incorporation into the dough. The impact on the in vitro assessed bioavailability of ferulic acid was a 5-fold increase over the normal bran enriched wholegrain bread in a gastrointestinal model. Therefore in our study we will compare the kinetics and total bioavailability of ferulic acid from wholegrain breads enriched in native or pretreated bran. Furthermore, the colonic metabolism of ferulic acid and overall major colonic metabolites such as short chain fatty acids (SCFA) will be studied. Finally, total antioxidant capacity and ex vivo inflammatory responses will be investigated in order to determine the effect of the pretreatment of on the immunomodulatory properties of bran.

Objective: The aim of the present study is to investigate the effect of pretreatment of bran on improving the bioavailability of ferulic acid. As secondary endpoints we will investigate the changes in plasmatic antioxidant capacity, anti-inflammatory effects, colonic metabolites from ferulic acid and short chain fatty acids (SCFA).

Study design: Blind, cross-over, randomised design. Wash-out period of one week. Three days of low antioxidant diet. Standardised meal low in phenolic and antioxidant compounds will be consumed the evening before the trial.

Study population: Healthy male volunteers, > 18 yr old, BMI between 20 and 30. Intervention: Consumption of 300 g of wholegrain enriched with native or pretreated bran.

Main study parameters/endpoints: Ferulic acid and other phenolic acids (sinapic acid, p-coumaric acid), total antioxidant capacity, anti-inflammatory effects, colonic metabolites derived from ferulic acid and SCFA.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Each volunteer will participate in the study on two separate occasions (each test will take approximately 24 hours). Blood will be drawn at different time points via a catheter (in total 156 ml per test-day) and a 24-hour urine sample will be collected. Participants are asked to consume a standardised meal the evening before each of the two test-days and the evening of the intervention day. Volunteers are instructed not to consume any wholegrain or bran containing products, nuts and seeds, antioxidant supplements or beverages high in phenolic compounds or any phenolic rich food for 3 days before each of the three trials. Subjects are asked to record their food intake for 3 days before each of the trials. All the ingredients used in the bread baking are safe for human consumption. The bread is consumed once at the beginning of the test. The volunteers will not benefit from the study. The major risk of the study is the amount of blood take from the volunteer and this risk is limited.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date December 2009
Est. primary completion date November 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy males

- Age > 18

- 20 < BMI < 30

Exclusion Criteria:

- Use of any medication

- Smoking

- Consumption of 3 or more glasses of alcoholic drinks per day

- Donation of more than 500 ml blood (<6 months prior to the start of the study)

- Vegetarian lifestyle (because the standardised meal contains meat)

- Allergic reaction to some component in cereals e.g. celiac subjects

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ferulic acid
Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
Dietary Supplement:
Treated bran bread
This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
wholegrain bread
The control is the wholegrain bread enriched with bran that has not been pretreated

Locations

Country Name City State
Netherlands University of Maastricht Maastricht

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ferulic acid is measured in plasma to determine maximal concentration (Cmax), time-point of Cmax (tmax) and area under the curve (AUC). Ferulic acid is also measured in 24-hour urine sample to determine its excretion. 24 h
Secondary Colonic metabolites derived from ferulic acid, short chain fatty acids and antioxidant capacity are measured in plasma to determine their relation with the plasma levels of ferulic acid. Cytokines will be measured in ex vivo LPS stimulated blood. 24 h
See also
  Status Clinical Trial Phase
Recruiting NCT04234594 - Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males. Phase 1
Completed NCT01367561 - Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function Phase 1
Recruiting NCT04756635 - Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity N/A
Completed NCT02156661 - Oxytocin and Emotion Processing Phase 1
Completed NCT01848665 - The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress Phase 4
Completed NCT05294198 - Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males N/A
Completed NCT00839319 - HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone Phase 1/Phase 2
Completed NCT00842751 - Oral T7 Oral Testosterone in Man Phase 2
Completed NCT01847053 - Bioavailability Study of Cinnamon in Healthy Subjects Phase 1/Phase 2
Completed NCT01215292 - ITT4 Intratesticular Hormonal Milieu in Man (ITT4) Phase 1/Phase 2
Completed NCT00782392 - Bioavailability and Dosing of a Monosaccharide Supplement in Adults N/A
Completed NCT03714685 - Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations Phase 1
Completed NCT05277597 - Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota N/A
Completed NCT01032616 - Uptake and Utilization of Amino Acids by Splanchnic Bed Phase 1
Completed NCT01830335 - Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Phase 4
Completed NCT00902512 - Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations Phase 4
Completed NCT00475371 - A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males Phase 1
Completed NCT01870102 - Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects Phase 1